Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-T for MRD in B-cell Malignancies After ASCT
NCT03564977Unknown
- Sponsor
- Affiliated Qingdao Central Hospital of Qingdao University
- Start
- Jul 2018
- Primary completion
- Jun 2020
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Open-label, single-arm trial of Sino19 in B cell lymphoma, B-cell leukemia (BCL) and minimal residual disease (MRD), sponsored by Affiliated Qingdao Central Hospital of Qingdao University. Primary endpoints: Objective Response Rate at 2 years, Disease Control Rate at 2 years and 2 more. Status: unknown.
02
Drugs
Sino19
03
Conditions
B cell lymphomaB-cell leukemia (BCL)minimal residual disease (MRD)
Beyond the preview
Go deeper on NCT03564977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03564977.